Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Kiadis Pharma NV (KDS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Kiadis Pharma historical data, for real-time data please try another search
5.460 0.000    0.00%
24/05 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 5.370 - 5.460
Type:  Equity
Market:  Netherlands
ISIN:  NL0011323407 
Kiadis Pharma 5.460 0.000 0.00%

Kiadis Pharma Company Profile

 
Read the Kiadis Pharma NV company profile to learn more about the business and the management team. View Kiadis Pharma NV facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

103

Equity Type

ORD

Kiadis Pharma N.V., a biopharmaceutical company, develops NK-cell-based medicines for the treatment of life-threatening diseases in the Netherlands. Its lead product candidate is K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol, as well as for the treatment of liquid and solid tumors and infectious diseases; and K-NK003 that is in Phase II clinical study for the treatment of patients with acute myeloid leukemia relapse/refractory. The company is also developing K-NK-ID101, which is in Phase I/II a clinical trial for the treatment of COVID-19 infection; K-NK00X, which is in preclinical stage with K-NK-cell therapies for the treatment of hematologic and solid cancers; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for a range of other cancers and infectious diseases. It has a collaboration agreement with Sanofi. The company was founded in 1997 and is based in Amsterdam, Netherlands. Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.

Contact Information

Address Paasheuvelweg 25A
Amsterdam, 1105 BP
Netherlands
Phone 31 20 240 5250
Fax 31 20 240 5251
Web
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

KDS Price Commentary

Write your thoughts about Kiadis Pharma NV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email